Cytokinetics evaluates CK-2127107 in Phase II trial to treat ALS

US-based Cytokinetics has started a Phase II FORTITUDE-ALS clinical trial of CK-2127107 for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news